Baldur Sveinbjørnsson
ArticleNeoadjuvant intratumoural immunotherapy: leveraging the primary tumour as a patient‑specific in vivo vaccine site
Baldur Sveinbjørnsson, Chief Scientific Officer of Lytix Biopharma, discusses how the clinical insights from the Phase II NeoLIPA trial of neoadjuvant intratumoral therapy could inform the future of neoadjuvant trial design.